- Trials with a EudraCT protocol (4,659)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,659 result(s) found for: Day care.
Displaying page 12 of 233.
EudraCT Number: 2015-000882-29 | Sponsor Protocol Number: 001 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:Reinier de Graaf Groep | |||||||||||||
Full Title: Spinal hyperbaric Prilocaine 2% 60 or 80 mg: a dosing study in day care patients. | |||||||||||||
Medical condition: spinal anesthesia for open inguinal hernia repair or lower limb surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001696-32 | Sponsor Protocol Number: GC2004 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo... | ||||||||||||||||||
Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023747-15 | Sponsor Protocol Number: 070411 | Start Date*: 2011-05-03 | |||||||||||
Sponsor Name:University of Oslo | |||||||||||||
Full Title: Tick borne diseases in norwegian general practice. A randomized, controlled trial for treatment of erythema migrans in norwegian general practice. A comparison of phneoxymetylpenicillin, amoxicilli... | |||||||||||||
Medical condition: Erythema migrans (Early Lyme disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001923-11 | Sponsor Protocol Number: 18-BI-1206-03 | Start Date*: 2019-12-09 | |||||||||||
Sponsor Name:BioInvent International AB | |||||||||||||
Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL... | |||||||||||||
Medical condition: Advanced solid tumors who have relapsed or are refractory to anti-PD1 or anti-PDL1 therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003450-22 | Sponsor Protocol Number: P-105-303 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar... | |||||||||||||
Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002857-28 | Sponsor Protocol Number: C4671002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI... | |||||||||||||
Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) BG (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001255-40 | Sponsor Protocol Number: STRIKE-SARS-CoV2 | Start Date*: 2020-04-16 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19. | |||||||||||||
Medical condition: Severe pneumonia caused by infection with SARS CoV 2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002148-56 | Sponsor Protocol Number: ACT-CS-005 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:ACTICOR BIOTECH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004055-37 | Sponsor Protocol Number: ALXN1830-WAI-201 | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | |||||||||||||
Medical condition: WAIHA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001693-15 | Sponsor Protocol Number: IPPCollapse-II | Start Date*: 2016-08-08 |
Sponsor Name:INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE | ||
Full Title: Individualized Pneumoperitoneum Pressure in Colorectal laparoscopic surgery versus standard therapy (IPPCollapse II) | ||
Medical condition: Pneumoperitoneum Pressure in Colorectal laparoscopic surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001701-13 | Sponsor Protocol Number: FFAKI | Start Date*: 2015-09-19 | |||||||||||||||||||||
Sponsor Name:Nordsjællands Hospital. Dept. of Anaesthesiology and Intensive Care. | |||||||||||||||||||||||
Full Title: Forced fluid removal vs. usual care in intensive care patients with high-risk acute kidney injury and severe fluid overload (FFAKI) – A randomized clinical trial | |||||||||||||||||||||||
Medical condition: Fluid overload associated with acute kidney injury in patients admitted to the intensive care unit | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003184-65 | Sponsor Protocol Number: TPL107 | Start Date*: 2020-02-24 |
Sponsor Name:Vifor Pharma | ||
Full Title: POREIIL - Postoperative replacement of intraoperative iron losses | ||
Medical condition: perioperative bleeding induced iron losses and anemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000182-33 | Sponsor Protocol Number: 76421 | Start Date*: 2021-03-25 |
Sponsor Name:Radboudumc | ||
Full Title: Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers | ||
Medical condition: Immunogenicity of the mRNA BNT162b2 COVID-19 vaccine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003168-37 | Sponsor Protocol Number: Thllo | Start Date*: 2019-05-13 |
Sponsor Name:University Tuebingen | ||
Full Title: Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study | ||
Medical condition: Acute respiratory distress syndrome requiring mechanical ventilation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002617-33 | Sponsor Protocol Number: VS01IIa01 | Start Date*: 2022-08-17 | |||||||||||
Sponsor Name:Versantis AG | |||||||||||||
Full Title: A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety and tolerability of VS-01 on top of standard of care, compared to standard of ca... | |||||||||||||
Medical condition: Acute-on-chronic liver failure (ACLF) is characterized by hepatic and extrahepatic organ dysfunction and/or failure and highly activated systemic inflammation. It leads to an accumulation of differ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004610-29 | Sponsor Protocol Number: 2014.001 | Start Date*: 2015-02-18 |
Sponsor Name:Skanes University Hospital | ||
Full Title: Ciclosporin to Protect Renal function In Cardiac Surgery. CiPRICS. A Phase II Double Blind Randomized Placebo Controlled Study. | ||
Medical condition: Renal dysfunction after CABG surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023104-28 | Sponsor Protocol Number: MEIN/10/Neb+HCTZ-Hyp/001 | Start Date*: 2011-10-20 | |||||||||||
Sponsor Name:Menarini International Operations Luxembourg S.A. | |||||||||||||
Full Title: A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly pa... | |||||||||||||
Medical condition: Isolated Systolic Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002275-34 | Sponsor Protocol Number: WA42511 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REMDESIVIR PLUS TOCILIZUMAB COMPARED WITH REMDESIVIR PLUS PLACEBO IN HOSPITALIZED PATIENTS WITH SEVER... | |||||||||||||
Medical condition: Severe coronavirus disease 2019 (COVID-19) pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002913-16 | Sponsor Protocol Number: 0135-0347 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome caused by Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
